Thyroid function testing is recommended by international guidelines for all blood and marrow transplant (BMT) survivors yearly after the procedure or if new relevant symptoms develop. 1 The occurrence of thyroid dysfunction (TDF) as a complication of BMT and the factors associated with it have been described primarily in pediatric recipients of allogeneic BMT. [2] [3] [4] However, fewer studies have analyzed the incidence of this complication in adults, [5] [6] [7] in particular after autologous BMT. 5 In this study, we retrospectively analyzed the incidence of TDF in all consecutive adult BMT recipient survivors from our center for whom serial monitoring of thyroid-stimulating hormone (TSH) and free T4 (FT4) levels were available (n ¼ 169 adults; Table 1 ). This population is representative of the overall BMT population for the same period (February 1993-April 2008) in terms of patient and transplant characteristics, such as type of BMT (autologous vs allogeneic), type of allogeneic donor (related vs unrelated), type of conditioning for allogeneic BMT (myeloablative vs non-myeloablative), gender, age at BMT, underlying disease and source of progenitors (data not shown).
Out of 169 patients included in the study, 62 (37%) developed TDF after BMT, including 54 cases of subclinical hypothyroidism (increased TSH, normal FT4 and no clinical symptoms; 32%), 6 cases of overt primary hypothyroidism (increased TSH and reduced FT4; 4%) and 2 additional cases of subclinical hyperthyroidism (reduced TSH and normal FT4; 1%). All cases of primary hypothyroidism started oral L-thyroxine replacement therapy. Their dose of L-thyroxine is adjusted when required, based on hormone level assessments performed at 6-monthly intervals. Cases of subclinical TDF are monitored periodically, including cases of subclinical hyperthyroidism, which maintain detectable TSH levels (0.1-0.4 mU/L), are younger than 60 years of age, have normal bone mineral density, no underlying heart disease or symptoms of hyperthyroidism, are in keeping with endocrinology review, and have not required treatment to date. The onset of TDF took place overall at a median of 39 months after BMT (mean 55; range 8-169), with more than 25% of cases first developing it between 7 and 14 years after BMT (third quartile 94 months). In particular, TDF after autologous BMT had a significantly longer time to onset (median 47 months, mean 63, range 9-169) than after allogeneic BMT (median 18 months, mean 23, range 8-58; P ¼ 0.010). One-quarter of the TDF cases after autologous BMT in our series presented nearly 9 years or longer after the procedure, a finding that reinforces the relevance of long-term monitoring to assess the real impact of TDF in this population. Indeed, the effect of the type of BMT on the risk of TDF as a time-dependent variable was non-proportional over time, as there were no differences in cumulative incidence of TDF in the first 5 years (autologous 29.9% vs allogeneic 30.3%), but from year 5 onwards our data showed a statistical trend toward a higher cumulative incidence of TDF after autologous than after allogeneic BMT (relative risk: 3.5, 95% confidence interval 0.92-8.3, P ¼ 0.06). In keeping with this finding, the overall prevalence of TDF was higher after autologous than after allogeneic BMT (43 vs 24%, respectively; P ¼ 0.020, chi-square), despite both groups having comparable median lengths of follow-up (autologous 69 months vs allogeneic 63 months; P ¼ 0.202). Cumulative incidence was calculated using NCSS 97 (Kaysville, UT, USA) and all other computations using SPSS 15.0 (Chicago, IL, USA).
The reported incidence of TDF after BMT in adults ranges from 10 to 47% in the three studies available in the literature. [5] [6] [7] These studies focused on allogeneic BMT, and only one of them, by Somali et al., 5 included cases of autologous BMT, showing no difference in their incidence of TDF compared with their allogeneic BMT counterparts. This negative finding in Somali's study is not surprising if we take into consideration both the lower number of cases included in the study (29 autologous and 43 allogeneic) and their shorter follow-up time of only 1.5 years, considering our findings on the late onset of TDF after autologous BMT. 5 Other than type of BMT, we found no statistically significant association in adult long-term BMT survivors between TDF and patient or transplant characteristics such as age, gender, underlying disease, hematopoietic cell source, type of conditioning for allogeneic BMT, type of allogeneic donor and exposure to radiotherapy, either as TBI for conditioning (X12 Gy divided into four fractions in all cases) or as any radiation exposure including pretransplant radiotherapy involving the thyroid gland in 12 additional lymphoma patients (Table 1) . TBI has been clearly linked to the occurrence of TDF after BMT in a large series of 791 children. 2 Our data in adults suggest otherwise, and there is an additional manuscript from another group reporting no difference in the incidence of post-transplant hypothyroidism between TBI-based myeloablative and chemotherapy-based reduced-intensity conditioning regimens in a series of 181 adult allogeneic BMT recipients. 8 We may argue that adults are less sensitive than children to the endocrine side effects from radiation, but, nevertheless, any negative findings of a retrospective analysis of this size have the potential caveat of inadequate statistical power and must be interpreted with caution.
In conclusion, our results show that adult survivors of BMT are at an increased risk of TDF for many years after the procedure. Moreover, they suggest that the cumulative incidence and prevalence of TDF in recipients of autologous BMT may be higher than expected to date, and that this high risk persists long after BMT, with nearly a quarter of the cases of TDF after autologous BMT developing more than 9 years after the procedure. This high incidence may have been underestimated previously as a result of shorter follow-up. Finally, these data strongly suggest that the current recommendations for sustained long-term monitoring of thyroid function tests in adult BMT recipients should be reinforced, not only after allogeneic but also particularly after autologous BMT.
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